Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection

Virology Journal

Volumn 9, Issue , 2012, Pages

  Rivière, Yves ^a   Montange, Thomas ^a   Janvier, Geneviève ^a   Marnata, Caroline ^a   Durrieu, Ludovic ^a,f   Chaix, Marie Laure ^b   Isaguliants, Maria ^c   Launay, Odile ^d   Bresson, Jean Louis ^e   Pol, Stanislas ^d  

^a CNRS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d CIC de Vaccinologie Cochin Pasteur Inserm CIC BT505 ^*  (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Elispot; HCV; Inapparent infection; Prevalence; Proliferation

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; VIRUS ANTIGEN;

ADULT; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; EX VIVO STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; INFLUENZA VIRUS; LONG TERM EXPOSURE; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; RISK; VIRUS DETECTION; HUMAN EXPERIMENT; IMMUNOLOGY; MONONUCLEAR CELL; PREVALENCE;

HEPATITIS C VIRUS; HUMAN HERPESVIRUS 5; ORTHOMYXOVIRIDAE;

ANTIGENS, VIRAL; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEPACIVIRUS; HUMAN EXPERIMENTATION; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTES, MONONUCLEAR; MALE; PREVALENCE;

EID: 84862018409     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422x-9-76     Document Type: Article

References (39)

1. Allain JP: Hepatitis C virus in blood donation. Lancet 2005, 365:276-278.
2. Semmo N, Barnes E, Taylor C, Kurtz K, Harcourt G, Smith N, et al: T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005, 365:327-329. (Pubitemid 40139110)
3. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al: Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007, 4(58):1-11.
4. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature medicine 2000, 6:578-582. (Pubitemid 30305910)
5. Widell A, Busch M: Exposed or not exposed-that is the question: evidence for resolving and abortive hepatitis C virus infections in blood donors. Transfusion 2009, 49:1277-1281.
6. Post JJ, Ratnarajah S, Llyod AR: Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009, 66:733-756.
7. Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al: Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004, 78:11252-11258.
8. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KMC, Reichen J, et al: Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999, 190:169-176. (Pubitemid 29354910)
9. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B: Crossreactivity between hepatitis C virus and Influenza A virus determinantspecific cytotoxic T cells. J Virol 2001, 75:11392-11400. (Pubitemid 33063230)
10. Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, et al: The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology 2006, 43:602-611.
11. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G: for the GERMIVIC Study Group. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepatitis 2006, 13:775-782. (Pubitemid 44583504)
12. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, et al: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260:157-172. (Pubitemid 34132882)
13. Thimme R, Neumann-Haefelin C, Boettler T, Blum HB: Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008, 389:457-467. (Pubitemid 351874195)
14. Yusim K, Richardson R, Tao N, Szinger JJ, Funkhouser R, Korber B, et al: HCV HCV immunology database: the Los Alamos Hepatitis C Immunology Database. Appl Bioinforma 2005, 4:217-225. (Pubitemid 41737124)
15. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
16. McKinnon LR, Blake Ball T, Wachihi C, McLaren PJ, Waruk JLM, Mao X, et al: Epitope cross-reactivity frequently differs between central and effector memory HIV-specific CD8-T cells. J Immunol 2007, 178:3750-3756. (Pubitemid 46417643)
17. Bronowicki JP, Vetter D, Uhl G, Hudziak H, Uhrlacher A, Vetter JM, et al: Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCVseronegatives spouses of HCVinfected patients. J Infect Dis 1997, 176:518-527.
18. Jackson M, Smith B, Bevitt DJ, Steward M, Toms GL, Bassendine MF, et al: Comparison of cytotoxic T lymphocyte responses to Hepatitis C virus core protein in uninfected and infected individuals. J Med Virol 1999, 58:239-246. (Pubitemid 29278026)
19. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD: Hepatitis C virusspecific cytolytic T lymphocyte and T helper responses in seronegative persons. J Infect Dis 1997, 176:859-867.
20. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al: Presence of effector CD8+ T cells in Hepatitis C virus exposed healthy seronegative donors. J Immunol 1999, 162:6681-6689. (Pubitemid 29309393)
21. Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, et al: Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009, 16:10-20.
22. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al: Clearance of hepatitis C viremia associated with cellular in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004, 189:1846-1855. (Pubitemid 38657221)
23. Hashem M, El-Karksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, et al: Strong Hepatitis C Virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis 2011, 203:854-861.
24. Altschul SF, Madden TM, Schäffer AA, Zhang J, Zhang Z, Miller W, et al: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25:3389-3402. (Pubitemid 27359211)
25. Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar-Daughton C, et al: Correlation between Interferon-γ Secretion and Cytotoxicity in Virus- Specific Memory T Cells. J Infect Dis 2004, 190:1692-1696. (Pubitemid 39411021)
26. Littaua RA, Oldstone MBA, Atakeda A, Ennis FA: A CD4+ Cytotoxic TLymphocyte Clone to a Conserved Epitope on Human Immunodeficiency Virus Type 1 p24: Cytotoxic Activity and Secretion of Interleukin-2 and Interleukin-6. J Virol 1992, 66:608-611.
27. Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA: Human Cytotoxic T-Cell Memory: Long-Lived Responses to Vaccinia Virus. J Virol 1996, 70:2627-2631. (Pubitemid 26087631)
28. Puissant-Lubrano B, Bossi P, Gay F, Crance JM, Bonduelle O, Garin D, et al: + effector/memory CD4+ lymphocytes in humans + TNF-a Control of vaccinia virus skin lesions by long-term-maintained IFN-g. J Clin Invest 2010, 120:1636-1644.
29. Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V: Cellular immune responses associated with occult hepatitis C virus infection in the liver. J Virol 2006, 80:10972-10979. (Pubitemid 44706538)
30. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, et al: Occult hepatitis C infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004, 189:7-14. (Pubitemid 38122323)
31. Poynard T, Lebray P, Ingiliz P, Varaut A, Ngo Y, Norha P, et al: Prevalence of liver fibrosis and risk factors in a general population usng non-invasive biomarkers (Fibrotest). BMC Gastroenterol 2010, 10:4.
32. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:369-401.
33. Thomas DL, Chloe L, Thio CL, Maureen P, Martin MP, Qi Y, Dongliang Ge D, O'hUigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Sharyne M, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington Mary: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-802.
34. Jensen DM, Pol S: IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int 2012, 32:74-78.
35. Janvier G, Chaix ML, Fontaine H, Bresson JL, Pol S, Rivière Y: The corespecific precursor T cell response is directed to the N-terminal and central parts of the protein and positively correlates to the viral load in chronically HCV-infected patients. Virology 2005, 340:318-325. (Pubitemid 41317505)
36. Kuiken C, Mizokami M, Deleage G, Yusim K, Penin F, Shin-I T, et al: Hepatitis C Databases, Principles and Utility to Researchers. Hepatology 2006, 143:1157-1165. (Pubitemid 43724642)
37. Kuiken C, Yusim K, Boykin L, Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics 2005, 21:379-384. (Pubitemid 40246609)
38. Buseyne F, Catteau A, Scott-Algara D, Corre B, Porrot F, Rouzioux C, et al: A Vaccinia-based Elispot assay for detection of CD8+ T cells from HIV-1 infected children. J Immunol Methods 2005, 298:105-118. (Pubitemid 40545097)
39. Lyons AB: Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243:147-154.